Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 2, 2020 (6 years ago)

Cefdinir for Oral Suspension USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Cefdinir for Oral Suspension USP, 250 mg/5mL, packaged in 60 mL bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India, NDC 68180-723-20

Affected NDC 68180-0723-20

Compare with the code on your package — it is the most precise check available.

Drug: Cefdinir

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Cefdinir
NDC 68180-0723
250 mg/5mL Powder, for Suspension
Oral
Lupin Pharmaceuticals, Inc. Rx
Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
68180-723-20
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1406-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cefdinir recalls

See all

Other recalls by Lupin Pharmaceuticals Inc.

All 2020 recalls